2 active not recruiting, 1 completed. 1 Early Phase 1, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Active not recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow CEBIOTEX: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CEB-01 in Pediatrics With Locally Resectable Abdominal Tumors Standard surgery, CEB-01 - Locally Resectable Pediatrics Tumors | Phase 2 | Active not recruiting | CEBIOTEX | 80 | 2025-05-06 | 2026-10-20 |
| CEB-01 in Locally Resectable Pancreatic Cancer Standard surgery, CEB-01 - Pancreatic Carcinoma | Early Phase 1 | Active not recruiting | CEBIOTEX | 39 | 2024-08-20 | 2026-10-14 |
| First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma CEB-01 membrane loaded with SN-38 - Locally Advanced Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma | Phase 1 | Completed | CEBIOTEX | 21 | 2020-06-03 | 2026-05-12 |
Pancreatic Neoplasms (1) · Recurrence (1) · Sarcoma (1)
Irinotecan (1)
Spain (3)
Ana Sebio, M.D. Ph.D. (1) · Javier Padillo Ruiz, M.D.; Ph.D. (1) · Marta Pilar Martin Gimenez, M.D.; Ph.D. (1)
PMID 41984420, PMID 41984421, PMID 41998462
2018 (1)